A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

As one of the most common malignant tumors in women, the incidence of ovarian cancer is expected to increase year by year. Due to its lack of typical symptoms and effective screening methods, and the characteristics of implantation and distant metastasis, more than 70% of ovarian cancers were in the metastatic stage at the time of diagnosis. In this study, the investigators will collect large samples of tissue from patients with ovarian cancer, conduct multi-omics studies, and mapped the characteristic maps of the genome and transcriptome of patients with metastatic ovarian cancer, and explore the molecular mechanisms that can be used as new targets for the treatment of ovarian cancer. Besides, the investigators will design and establish a database of metastatic ovarian cancer, integrate multiple omics, imaging, pathology, and clinical information to study their potential relevance, and analyze the relationship between various omics, imaging, pathology, and prognosis, establish ovaries Cancer prediction model.

Inclusion Criteria:

1. female, ≥18 years old;
2. diagnosed as ovarian cancer by imaging and pathology;
3. did not receive any anti-tumor drug treatment before surgery in the gynecology clinical department of the Sun Yat Sen Memorial Hospital of Sun Yat-Sen University;
4. received ovarian cancer surgery and Follow-up treatment;
5. Patients voluntarily participate in the research of this subject, have good compliance, and can complete the enrollment by the requirements of the trial;
6. Sign informed consent and agree to the collection and use of their data.

Exclusion Criteria:

1. Patients who have received other anti-tumor treatments or received tumor surgery before enrollment;
2. Patients with malignant tumors in other parts;
3. Patients with uncontrollable neurological, psychiatric, or mental disorders;
4. Poor compliance and inability to Cooperate and describe treatment responders.